-
Darbepoetin alfa (Cresp) Boosts Hemoglobin Levels in Chemotherapy-Induced Anemia (CIA): Results of Indian Analysis
04 Apr 2025 09:45 GMT
… 13% developing it during treatment1.
Cresp contains Darbepoetin alfa; an Erythropoietin … required blood transfusions. After treatment with Cresp, blood transfusion … cancer patients undergoing chemotherapy. Treatment with Cresp significantly improved …
-
Study: Darbepoetin alpha does not improve long-term HDFN outcomes
19 Mar 2025 03:31 GMT
… assess the neurodevelopmental effects of darbepoetin treatment for HDFN two years after … -center, phase 2 trial testing the efficacy of darbepoetin alpha. The patients … produce more red cells. The drug has been shown to reduce …
-
Erythropoietin (EPO) Drugs Market Forecast To Surge USD 12.5 Billion By 2033, Driven By 5.20% CAGR
07 Feb 2025 09:58 GMT
… for anemia treatment, while darbepoetin-alfa remains … in drug discovery, personalized medicine, and … necessitate extensive clinical trials and data, … Pharmaceuticals
•GlycoMimetics Inc.
•Akebia Therapeutics
Emerging Trends in Erythropoietin (EPO) Drugs …
-
Erythropoietin Drugs Market: Trends and Insights | CAGR of 5.7%
28 Jan 2025 07:06 GMT
… from ESRD treatments and dialysis procedures. EPO drugs have gained … contrary, the commercialization of darbepoetin alfa biosimilar and achieving economies … Sciences Ltd.
Teva Pharmaceutical Industries Ltd.
Intas Pharmaceuticals
Ranbaxy Laboratories Ltd., …
-
Treatment Inertia and Symptom Burden in Anemia of CKD: Insights from the SATISFY Survey in the Middle East, South Africa, and Türkiye
21 Jan 2025 18:11 GMT
… but it has a higher drug acquisition cost compared with other … initiate treatment and the actual reported test levels from medical records … are not addressed in clinical trials, which only include patients … CY, et al. A trial of darbepoetin alfa in type 2 …
-
Subcutaneous Biologics Market, Industry Trends And Global Forecasts To 2035: Subcutaneous Biologics Set To Transform Drug Delivery And Patient Adherence
16 Jan 2025 13:02 GMT
… offering targeted treatments with minimal drug interactions. … (Amgen) STELARA (Janssen Biotech) Trulicity (Eli Lilly) … Alteogen Foresee Pharmaceuticals SUBCUTANEOUS FORMULATION TECHNOLOGIES … ACTHar AIMOVIG AJOVY AMVUTTRA Aranesp / NESP Basaglar …
-
Myelodysplastic Syndrome Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies By Delveinsight
27 Dec 2024 12:56 GMT
… the BEXMAB trial that evaluates … Drug Administration (FDA) has approved TIBSOVO (ivosidenib tablets) for the treatment … Corporation
Darbepoetin Alfa:
Amgen
ASTX727 LD:
Astex Pharmaceuticals
… Myelodysplastic Syndrome Current Treatment and Medical Practices
10. …
-
3 Biotech Stocks Revolutionizing Cancer Treatment
10 Dec 2024 20:28 GMT
… fundamentally strong biotech stocks: Regeneron Pharmaceuticals, Inc … Drug Administration (FDA) approved 16 oncology drugs … trial is designed to explore a novel, chemotherapy-free, fixed duration treatment … , Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO …
-
Exploring drug shortages in European markets: the causes, analysis, and response
25 Nov 2024 12:43 GMT
… drug type undergoing shortages are generics. The president of the Medicines … shortages in Norway are Aranesp, Minirin, and … are impacted, including treatments for pain relief, schizophrenia … trials and manufacturing expertise of GlobalData’s Pharmaceutical …
-
3 Biotechnology Stocks With Promising Pipelines
02 Nov 2024 00:15 GMT
… strong biotech stocks Amgen Inc. (AMGN), Regeneron Pharmaceuticals, … medicine, and rapid acceleration in drug … Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, … FDA approval for Dupixent® (dupilumab) as an add-on maintenance treatment …
About
© 1995-2025